Literature DB >> 19844815

Tamoxifen and arrhythmia.

Ladislav Slovacek, Peter Priester, Jiri Petera, Jindrich Kopecky.   

Abstract

Tamoxifen is an orally active selective estrogen receptor modulator that is used in the treatment of breast cancer and is currently the world's largest selling drug for that purpose. However, it has some side effects including hot flashes, menstrual irregularity, vaginal discharges, uterine bleeding, uterine endometrial cancer, hypercoagulability, steatosis hepatis, risk of trombembolism. Long-term data from clinical trials have failed to demonstrate a cardioprotective effect and beneficial effects on serum lipid profiles. Arrhythmia secondary to tamoxifen is very rare.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19844815     DOI: 10.1007/s12032-009-9334-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  4 in total

1.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Authors:  Yan Jin; Zeruesenay Desta; Vered Stearns; Bryan Ward; Herbert Ho; Kyung-Hoon Lee; Todd Skaar; Anna Maria Storniolo; Lang Li; Adjei Araba; Rebecca Blanchard; Anne Nguyen; Lynda Ullmer; Jill Hayden; Suzanne Lemler; Richard M Weinshilboum; James M Rae; Daniel F Hayes; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2005-01-05       Impact factor: 13.506

2.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

Authors:  H Kim Crewe; Lisa M Notley; Rebecca M Wunsch; Martin S Lennard; Elizabeth M J Gillam
Journal:  Drug Metab Dispos       Date:  2002-08       Impact factor: 3.922

3.  Tamoxifen induced-thrombocytopenia: it does occur.

Authors:  Narin Nasiroğlu; Merve Pamukçuoğlu; Hüseyin Abali; Berna Oksüzoğlu; Ayşegül Uner; Nurullah Zengin
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  Tamoxifen-induced QT interval prolongation.

Authors:  L Slovacek; V Ansorgova; Z Macingova; L Haman; J Petera
Journal:  J Clin Pharm Ther       Date:  2008-08       Impact factor: 2.512

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.